Traders Buy Large Volume of Rezolute Call Options (NASDAQ:RZLT)

Rezolute, Inc. (NASDAQ:RZLT) was the target of some unusual options trading on Friday. Investors bought 4,646 call options on the stock. This is an increase of approximately 137% compared to the average volume of 1,957 call options.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RZLT. BNP Paribas Financial Markets acquired a new position in Rezolute during the 2nd quarter worth $25,000. Russell Investments Group Ltd. acquired a new stake in shares of Rezolute in the 3rd quarter valued at $61,000. Ameritas Investment Partners Inc. bought a new stake in shares of Rezolute during the second quarter worth $30,000. Legal & General Group Plc acquired a new position in shares of Rezolute during the second quarter valued at $32,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Rezolute in the third quarter valued at about $94,000. Institutional investors own 82.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Guggenheim dropped their price objective on Rezolute from $15.00 to $6.00 and set a “buy” rating for the company in a research note on Friday. Maxim Group set a $4.00 target price on shares of Rezolute in a research report on Friday. JMP Securities set a $17.00 price target on shares of Rezolute in a report on Wednesday, October 29th. Cantor Fitzgerald cut shares of Rezolute from an “overweight” rating to a “neutral” rating in a research note on Thursday. Finally, Wall Street Zen lowered shares of Rezolute from a “hold” rating to a “sell” rating in a report on Saturday. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Rezolute currently has an average rating of “Moderate Buy” and an average price target of $9.78.

Rezolute Stock Up 28.6%

Shares of NASDAQ RZLT opened at $1.80 on Friday. Rezolute has a 12-month low of $1.07 and a 12-month high of $11.46. The firm’s 50-day simple moving average is $9.15 and its 200 day simple moving average is $7.15. The company has a market cap of $166.91 million, a price-to-earnings ratio of -1.94 and a beta of 0.21.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.09. On average, equities analysts expect that Rezolute will post -0.93 earnings per share for the current year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.